共 50 条
- [31] ISIS 449884 Injection Add-On to Metformin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical StudyDIABETES THERAPY, 2024, 15 (10) : 2183 - 2196Ji, LinongGao, LeiliFeng, ZhikaiChen, GuoliangFu, JingMorgan, ErinBhanot, SanjayGao, ShanZhang, HongyanLiang, ZicaiGan, Li
- [32] Retagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trialDIABETES OBESITY & METABOLISM, 2024, 26 (07): : 2830 - 2838Guo, LixinTian, FengshengLiu, LiChen, MingweiJiang, ChengxiaLi, ShuangqingLiu, CongZhang, YaweiQin, JieYu, DongniZong, YicenDai, Wei
- [33] Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes A 24-week, randomized, double-blind, placebo-controlled trialDIABETES CARE, 2013, 36 (11) : 3396 - 3404Haering, Hans-UlrichMerker, LudwigSeewaldt-Becker, ElkeWeimer, MarcMeinicke, ThomasWoerle, Hans J.Broedl, Uli C.
- [34] Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trialLANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (04): : 251 - 260Sorli, ChristopherHarashima, Shin-ichiTsoukas, George M.Unger, JeffreyKarsbol, Julie DervingHansen, ThomasBain, Stephen C.
- [35] A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozinDIABETES OBESITY & METABOLISM, 2024, 26 (06): : 2188 - 2198Lim, SooLee, Seung-HwanMin, Kyung-WanLee, Chang BeomKim, Sang YongYoo, Hye JinKim, Nan HeeKim, Jae HyeonOh, SeungjoonWon, Jong ChulKwon, Hyuk SangKim, Mi KyungPark, Jung HwanJeong, In-KyungKim, Sungrae
- [36] Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb studyANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (09) : 1147 - 1157Mease, Philip J.Chohan, SaimaFructuoso, Ferran J. GarciaLuggen, Michael E.Rahman, ProtonRaychaudhuri, Siba P.Chou, Richard C.Mendelsohn, Alan M.Rozzo, Stephen J.Gottlieb, Alice
- [37] Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study)Diabetology International, 2015, 6 (2) : 104 - 116Kashiwagi A.Shiga T.Akiyama N.Kazuta K.Utsuno A.Yoshida S.Ueyama E.
- [38] Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metforminDIABETES OBESITY & METABOLISM, 2014, 16 (12): : 1257 - 1264Reusch, J.Stewart, M. W.Perkins, C. M.Cirkel, D. T.Ye, J.Perry, C. R.Reinhardt, R. R.Bode, B. W.
- [39] Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled studyENDOCRINOLOGY DIABETES & METABOLISM, 2021, 4 (02)Ji, LinongLi, LingMa, JianhuaLi, XuefengLi, DongmeiMeng, BangzhuLu, WeipingSun, JiaoLiu, YanmeiTakayanagi, GenWang, Yi
- [40] Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT studyDiabetology International, 2015, 6 (2) : 125 - 138Kashiwagi A.Akiyama N.Shiga T.Kazuta K.Utsuno A.Yoshida S.Ueyama E.